- Neurotrope and Metuchen continue to move toward closing the previously announced merger
-Two separate publicly listed companies result: men's health company, Petros Pharmaceuticals, Inc. and Bryostatin-1 neurological disease company, Neurotrope Bioscience, Inc.
PR Newswire
NEW YORK, June 10, 2020